Syros Pharmaceuticals CMO sells over $50k in company stock

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Chief Medical Officer David Roth recently sold 10,451 shares of the company's common stock, according to the latest SEC filings. The transaction, which took place on April 3, 2024, amounted to a total of $51,732 at a price of $4.95 per share.

The sale was conducted under a pre-arranged trading plan, known as a 10b5-1 plan, which was adopted on March 27, 2023. These plans allow company insiders to set up a predetermined schedule to sell stocks at a time when they are not in possession of material non-public information, providing a legal defense against claims of insider trading.

Following the transaction, Roth's direct ownership in the company's stock dropped to zero, signaling a complete divestiture of his previously held shares. This move by the Chief Medical Officer is part of a routine disclosure required by corporate executives and other major shareholders.

Syros Pharmaceuticals, based in Cambridge, Massachusetts, operates in the pharmaceutical industry, focusing on the development of treatments for cancer and other diseases. The company's stock trades under the ticker symbol SYRS on the NASDAQ exchange.

Investors and market analysts often monitor insider sales as they can provide insights into an insider’s perspective on the company’s current valuation and future prospects. However, it's important to note that insider trading activities can be subject to various personal financial needs and strategies, and may not always reflect the executive's outlook on the company's future performance.

The detailed reporting of insider transactions is a regulatory requirement meant to ensure transparency in the financial markets, allowing investors to stay informed about significant trading activities by company insiders.

As Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) navigates the complexities of the pharmaceutical industry, recent market data and analysis from InvestingPro provide a deeper look into the company's financial health and stock performance. With Chief Medical Officer David Roth's complete divestiture of his shares, investors may seek additional context to understand the potential implications for their investment decisions.

An important metric to consider is the company's market capitalization, which currently stands at $123.54 million. The stock's recent performance shows a significant 1-month price total return of -32.59%, reflecting a notable decrease in value over the short term. Additionally, Syros Pharmaceuticals' Price / Book ratio, as of the last twelve months ending Q4 2023, is 7.41, suggesting a premium valuation compared to the book value of its assets.

Among the InvestingPro Tips, two insights stand out. Firstly, Syros holds more cash than debt on its balance sheet, which could be a sign of financial stability. Secondly, the Relative Strength Index (RSI) suggests that the stock is currently in oversold territory, which some investors might interpret as a potential buying opportunity. It's worth noting that the company has been quickly burning through cash, a situation reflected in its gross profit margin of -988.5% for the last twelve months as of Q4 2023, indicating significant challenges in generating profit from its revenues.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

For investors seeking a comprehensive analysis, there are additional Investing.com/pro/SYRS . Using the coupon code PRONEWS24, readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking an array of advanced metrics and insights to inform their investment strategies.